Company Overview and News
Even though generic drug supplier Teva Pharmaceutical Industries Limited (NYSE:TEVA) is nearly double from its bottom set last November, chances are good that Teva stock will continue moving up. The U.S. government is shifting its focus from accusing drug companies of overcharging to encouraging the marketplace to operate more competitively.
AGN TEVJF TEVA VRX TEVVF ENL ENDP
Dr. Reddy’s Laboratories Ltd. (RDY - Free Report) and Mylan (MYL - Free Report) announced that the FDA has approved the first generic version of a Suboxone (Buprenorphine and Naloxone Sublingual Film) under-the-tongue film for the treatment of opioid addiction. Both the companies will sell the generic version of the drug. Per the FDA, the approval was aimed at making the treatment available to more people.
INVVY IGXT SPG.PRJ AGLE IZQVF SPG ENL ILMN ENDP
BioMarin Pharmaceutical Inc (BMRN - Free Report) stated that it has dosed the first participant in a phase II study, evaluating its pipeline candidate, vosoritide, in pediatric patients with achondroplasia, a genetic disorder causing dwarfism in infants and toddlers.
SPG.PRJ CRSP SPG ENL BMRN ENDP
Kentucky's attorney general on Thursday sued Walgreens Boots Alliance Inc , accusing the company of playing a dual role in propagating an opioid epidemic in the state as both a pharmacy chain and wholesale drug distributor.
ABC MCK WBA CAH ENL ENDP
June 14 (Reuters) - Kentucky’s attorney general on Thursday sued Walgreens Boots Alliance Inc, accusing the company of playing a dual role in propagating an opioid epidemic in the state as both a pharmacy chain and wholesale drug distributor.
ABC MCK WBA CAH ENL ENDP
Tetraphase Pharma (TTPH) has a PDUFA on August 28 for its lead drug candidate ERAVACYCLINE in one indication - cIAI - complicated intra-abdominal infections. This PDUFA is based on an NDA filed on Feb 27 - the 6-month duration comes from a Fast Track designation; they also have a Qualified Infectious Disease Product (‘QIDP) for the drug candidate.
NTLA MKGAF OPK RCUS CORV ENL AQXP CUR EDIT ALXN AGN ADXS PFNX GTBP AMGN VTGN CRSP MDWD LLY SNY VICL LIVN MKGAY LIVN ENDP
The first-quarter 2018 Z.1 "flow of funds" report can be viewed in two ways. From one perspective, key conventional data are un-extraordinary. Household debt expanded at a 3.3% rate during the quarter, down from Q4's 4.6%. Home Mortgage borrowings slowed from 3.4% to 2.9%. Total Business debt grew at a 4.4% pace, unchanged from Q4 and down from Q1 '17's 6.1%. Financial sector borrowings were little changed, after expanding 1.
JD WSM UAA FMCKI FMCKJ TWTR FMCCO FMCCP FMCCM FMCCN FMCCI FMCCJ M FMCCG FMCKO FMCKP FMCKM FMCKN FMCKK FMCKL UA FMCC TSLA FIVE FMCCS ENDP FMCCT
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES
ASP ENL TRLPF ENDP
2018-03-29 - Asif
Overview Endo International plc is an Ireland-domiciled, global specialty pharmaceutical company focused on generic and branded pharmaceuticals. The company aim to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of generic and branded drugs to meet patients’ needs. Endo International plc was incorporated in Ireland in 2013 as a private limited company and re-registered effective February 18, 2014 as a public limited company. The company's ordinary shares are traded on the NASDAQ Global Market (NASDAQ) under the ticker symbol “ENDP.” References throughout to “ordinary shares” refer to Endo International plc’s ordinary shares, 1,000,000,000 authorized, par value $0.0001 per share. In addition, Endo International has 4,000,000 euro deferred shares outstanding, par value of $0.01 each. The company's global headquarters are located at Minerva House, Simmonscourt Road, Ballsbridge, Dublin 4, Ireland (telephone number: 011...
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
as of ET